Skip to Content
Merck
  • Use of racecadotril as outpatient treatment for acute gastroenteritis: a prospective, randomized, parallel study.

Use of racecadotril as outpatient treatment for acute gastroenteritis: a prospective, randomized, parallel study.

The Journal of pediatrics (2009-04-28)
Mar Santos, Rafael Marañón, Concepión Miguez, Paula Vázquez, Cesar Sánchez
ABSTRACT

To compare the efficacy of therapy with racecadotril plus oral rehydration versus oral rehydration alone in children with gastroenteritis in an outpatient setting care. Prospective, randomized, open and parallel study performed in a Pediatric Emergency Service of a tertiary care hospital. The study included 189 patients, ages 3 to 36 months, with acute gastroenteritis: 94 were administered an oral rehydration solution (OR), 94 received oral rehydration solution plus racecadotril (OR + R). The principal variable studied was the number of bowel movements in 48 hours after initiating treatment. The groups were comparable clinically and epidemiologically at enrollment. No significant differences were found in the number of bowel movements between the 2 groups 48 hours after initiating treatment (4.1 +/- 2.7 bowel movements in the OR group vs 3.8 +/- 2.4 bowel movements in the OR + R group). No differences were found in the average duration of gastroenteritis (4.7 +/- 2.2 days in the OR group, 4.0 +/- 2.1 days in the OR + R group; P = .15). The incidence of adverse events was similar in both groups (19 patients [20.2%] in the OR group, 18 patients [19.1%] in the OR + R group). In our study group, the use of racecadotril did not improve the symptoms of diarrhea compared with standard rehydration therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Racecadotril, ≥98% (HPLC)